April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Systemic Safety of Pegaptanib Sodium in the Treatment of Age-Related Macular Degeneration (AMD) in Subjects with Diabetes Mellitus (DM): A Pooled Analysis
Author Affiliations & Notes
  • Theresa M. Dombi
    CMO, Pfizer Inc, New London, Connecticut
  • Kenneth K. Kwoc
    Pfizer Inc, New York, New York
  • Robert L. Wiseman
    CMO, Pfizer Inc, New London, Connecticut
  • Marla B. Sultan
    Pfizer Inc, New York, New York
  • Footnotes
    Commercial Relationships  Theresa M. Dombi, Pfizer (E); Kenneth K. Kwoc, Pfizer (E); Robert L. Wiseman, Pfizer (E); Marla B. Sultan, Pfizer (E)
  • Footnotes
    Support  Research supported by Pfizer Inc.
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1666. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Theresa M. Dombi, Kenneth K. Kwoc, Robert L. Wiseman, Marla B. Sultan; Systemic Safety of Pegaptanib Sodium in the Treatment of Age-Related Macular Degeneration (AMD) in Subjects with Diabetes Mellitus (DM): A Pooled Analysis. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1666.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the incidence of prespecified Antiplatelet Trialists’ Collaboration (APTC) adverse events (AEs) in controlled AMD studies in subjects with DM treated with pegaptanib sodium 0.3 mg or sham injections.

Methods: : Using data from 9 controlled AMD clinical trials, APTC AEs identified by MedDRA preferred terms were retrospectively summarized and compared between pegaptanib vs sham injection-treated subjects with DM. All subjects with a history of DM who received treatment with 0.3 mg pegaptanib (by way of randomization, crossover design, protocol amendment, or change in dose assignment) or sham were included.

Results: : In all, 191 subjects with DM had been enrolled (165, pegaptanib; 26, sham); median age: 76.0 years. At least 1 APTC AE was reported for 13/191 subjects; the incidence was lower in the pegaptanib group occurring in 10/165 (6.1%; 13 events) pegaptanib- and 3/26 (11.5%; 3 events) sham-treated subjects. AEs were serious in 10/165 (6.1%, 12 events) and 2/26 (7.7%, 2 events), respectively. At least 1 severe APTC AE occurred in 6/165 (3.6%; 8 events) pegaptanib- and 2/26 (7.7%; 2 events) sham-treated subjects; 0/191 and 1/26 (3.8%) subjects, respectively, discontinued due to an APTC AE. Few subjects in either group reported APTC AEs, and those reported would be expected in an elderly diabetic population. Cerebrovascular accident (CVA) and myocardial infarction (MI) were reported for 3/165 (1.8%) and 2/165 (1.2%) pegaptanib-treated subjects and acute MI was reported for 1/26 (3.8%) sham-treated subject. No APTC AE was considered related to study treatment with the exception of 1 CVA, which was considered possibly related in a patient with history of DM, hypertension, and MI.

Conclusions: : The low number of subjects with DM makes it difficult to draw conclusions and to interpret between-group differences in individual AE’s. However, these findings, together with those reported previously in pegaptanib trials, suggest that there is no increased risk of APTC AEs for the diabetic population as a result of treatment with pegaptanib sodium 0.3 mg.

Keywords: vascular endothelial growth factor • clinical (human) or epidemiologic studies: risk factor assessment • age-related macular degeneration 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.